|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: POP5 |
Gene summary for POP5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | POP5 | Gene ID | 51367 |
| Gene name | POP5 homolog, ribonuclease P/MRP subunit | |
| Gene Alias | HSPC004 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0000966 | UniProtAcc | Q969H6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51367 | POP5 | LZE2T | Human | Esophagus | ESCC | 3.01e-02 | 4.38e-01 | 0.082 |
| 51367 | POP5 | LZE4T | Human | Esophagus | ESCC | 4.18e-13 | 3.56e-01 | 0.0811 |
| 51367 | POP5 | LZE5T | Human | Esophagus | ESCC | 3.51e-02 | 4.62e-01 | 0.0514 |
| 51367 | POP5 | LZE7T | Human | Esophagus | ESCC | 4.08e-17 | 8.81e-01 | 0.0667 |
| 51367 | POP5 | LZE8T | Human | Esophagus | ESCC | 1.81e-07 | 2.30e-01 | 0.067 |
| 51367 | POP5 | LZE20T | Human | Esophagus | ESCC | 8.26e-04 | 3.32e-01 | 0.0662 |
| 51367 | POP5 | LZE22D1 | Human | Esophagus | HGIN | 8.28e-08 | 3.81e-01 | 0.0595 |
| 51367 | POP5 | LZE22T | Human | Esophagus | ESCC | 8.25e-07 | 4.14e-01 | 0.068 |
| 51367 | POP5 | LZE24T | Human | Esophagus | ESCC | 1.02e-32 | 8.67e-01 | 0.0596 |
| 51367 | POP5 | LZE22D3 | Human | Esophagus | HGIN | 2.31e-03 | 4.38e-01 | 0.0653 |
| 51367 | POP5 | LZE21T | Human | Esophagus | ESCC | 2.24e-03 | 5.27e-01 | 0.0655 |
| 51367 | POP5 | LZE6T | Human | Esophagus | ESCC | 1.05e-09 | 5.97e-01 | 0.0845 |
| 51367 | POP5 | P1T-E | Human | Esophagus | ESCC | 9.21e-12 | 7.25e-01 | 0.0875 |
| 51367 | POP5 | P2T-E | Human | Esophagus | ESCC | 7.92e-59 | 1.05e+00 | 0.1177 |
| 51367 | POP5 | P4T-E | Human | Esophagus | ESCC | 6.90e-57 | 1.54e+00 | 0.1323 |
| 51367 | POP5 | P5T-E | Human | Esophagus | ESCC | 1.30e-54 | 1.11e+00 | 0.1327 |
| 51367 | POP5 | P8T-E | Human | Esophagus | ESCC | 1.10e-22 | 4.81e-01 | 0.0889 |
| 51367 | POP5 | P9T-E | Human | Esophagus | ESCC | 8.47e-21 | 4.96e-01 | 0.1131 |
| 51367 | POP5 | P10T-E | Human | Esophagus | ESCC | 2.87e-33 | 6.20e-01 | 0.116 |
| 51367 | POP5 | P11T-E | Human | Esophagus | ESCC | 4.47e-19 | 7.41e-01 | 0.1426 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
| GO:004225426 | Esophagus | HGIN | ribosome biogenesis | 101/2587 | 299/18723 | 8.74e-19 | 4.03e-16 | 101 |
| GO:001607219 | Esophagus | HGIN | rRNA metabolic process | 72/2587 | 236/18723 | 2.26e-11 | 2.56e-09 | 72 |
| GO:000636419 | Esophagus | HGIN | rRNA processing | 69/2587 | 225/18723 | 4.53e-11 | 5.04e-09 | 69 |
| GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
| GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:00905023 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 55/8552 | 82/18723 | 7.34e-05 | 5.51e-04 | 55 |
| GO:00344713 | Esophagus | ESCC | ncRNA 5'-end processing | 18/8552 | 21/18723 | 1.81e-04 | 1.16e-03 | 18 |
| GO:00009663 | Esophagus | ESCC | RNA 5'-end processing | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
| GO:00991163 | Esophagus | ESCC | tRNA 5'-end processing | 14/8552 | 16/18723 | 6.78e-04 | 3.56e-03 | 14 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| POP5 | SNV | Missense_Mutation | novel | c.136N>A | p.Ala46Thr | p.A46T | Q969H6 | protein_coding | tolerated(0.31) | benign(0.205) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| POP5 | SNV | Missense_Mutation | c.191N>C | p.Ile64Thr | p.I64T | Q969H6 | protein_coding | tolerated(0.21) | benign(0.026) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| POP5 | SNV | Missense_Mutation | novel | c.364C>A | p.Leu122Met | p.L122M | Q969H6 | protein_coding | tolerated(0.09) | probably_damaging(0.931) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| POP5 | SNV | Missense_Mutation | rs755497385 | c.139N>A | p.Ala47Thr | p.A47T | Q969H6 | protein_coding | deleterious(0.02) | probably_damaging(0.971) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| POP5 | SNV | Missense_Mutation | novel | c.85C>A | p.Leu29Met | p.L29M | Q969H6 | protein_coding | tolerated(0.12) | possibly_damaging(0.742) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| POP5 | SNV | Missense_Mutation | rs188049856 | c.167G>A | p.Arg56Gln | p.R56Q | Q969H6 | protein_coding | deleterious(0.01) | benign(0.182) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| POP5 | SNV | Missense_Mutation | novel | c.118G>C | p.Val40Leu | p.V40L | Q969H6 | protein_coding | tolerated(0.43) | benign(0.003) | TCGA-55-6987-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| POP5 | SNV | Missense_Mutation | c.486N>T | p.Met162Ile | p.M162I | Q969H6 | protein_coding | tolerated_low_confidence(0.45) | benign(0) | TCGA-85-6561-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD | |
| POP5 | SNV | Missense_Mutation | novel | c.435N>A | p.Ser145Arg | p.S145R | Q969H6 | protein_coding | tolerated(0.09) | benign(0.133) | TCGA-CQ-5325-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |